ClinicalTrials.gg
CompletedNCT04488978Updated Jun 30, 2022

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

A Phase 2 interventional study of Irbesartan/Amlodipine in Essential Hypertension, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-30.

Sponsored by Handok Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Enrollment
9th of 34
440 · median 314
Started
2020
the only one that year
Phase 2
4 of 34
none open now
Registered
26th of 34
by date
Lead sponsor
2 of 34
Handok Inc.

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 2, and was the 26th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are 19 years or older / 75 years or younger on screening
  • Signed
  • Patients with Essential Hypertension
  • Other inclusion applied

Exclusion criteria

Exclusion Criteria:

  • Orthostatic hypertension with symptom
  • Other exclusion applied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    Irbesartan low/Amlodipine low

    Irbesartan low \& Amlodipine low, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

  • Experimental
    Irbesartan low/Amlodipine high

    Irbesartan low \& Amlodipine high, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

  • Experimental
    Irbesartan high/Amlodipine low

    Irbesartan high \& Amlodipine low, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

  • Experimental
    Irbesartan high/Amlodipine high

    Irbesartan high \& Amlodipine high, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

  • Active comparator
    Amlodipine low

    Amlodipine low, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

  • Active comparator
    Amlodipine high

    Amlodipine high, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

  • Active comparator
    Irbesartan low

    Irbesartan low, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

  • Active comparator
    Irbesartan high

    Irbesartan high, once daily for 8 weeks

    Drug: Irbesartan/Amlodipine

Interventions

06

What researchers measure

Primary outcomes

  1. The change in MSSBP between baseline and Week8.

    The primary efficacy variable was the change in Mean Sitting Systolic Blood Pressure between baseline and Week8.

    Time frame: Baseline and Week8

Secondary outcomes

  1. The change in MSSBP between baseline and Week4.

    Time frame: Baseline and Week4

  2. The change in Mean Sitting Diastolic Blood Pressure between baseline and Week4 / Week8.

    Time frame: Baseline and Week4/8

  3. The proportion of patients having reached MSSBP < 140 mmHg and MSDBP < 90 mmHg at W4 and at W8.

    Time frame: Baseline and Week4/8

07

Study locations

1 site
  • Yonsei University Health System, Severance Hospital
    Seoul, 03722, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Nov 2021, 17 months.

Of 15 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2020
First posted
Jul 28, 2020
StartActual
May 21, 2020
Primary completionActual
Nov 9, 2021
CompletionActual
Nov 9, 2021
Last update
Jun 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04488978
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Jul 28, 2020
Start date
May 21, 2020
Primary completion
Nov 9, 2021
Completion
Nov 9, 2021
Last update
Jun 30, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irbesartan · Amlodipine

Start the discussion